برجاء الإنتظار ...

Search Results



نشرة الممارس الصحي نشرة معلومات المريض بالعربية نشرة معلومات المريض بالانجليزية صور الدواء بيانات الدواء
  SFDA PIL (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)

 

Sodium Chloride 0.45% w/v Intravenous Infusion B.P.

Composition

Each 100 ml contains:

Sodium Chloride

0.45 g

Water for Injection

Q.S.

Na+

77 mmol/L

Cl¯

77 mmol/L

pH

4.5 – 7.0

Theor. Osmolarity

154 mOsm/L

 


Contraindications

§ Hypernatraemia,

§ Acidosis,

§ Hypokalaemia

Precautions

Do not use if leakage was found, solution is cloudy or contains particles.

 


Intravenous infusion:

Up to 15 ml/kg BW/hr. i.e. 350 drops/minute/70 kg BW.

 

Average dosage:

1000 – 2000 ml/70 kg BW/day.


NA


Store below 25° C.


Each 100 ml contains:

Sodium Chloride

0.45 g

Water for Injection

Q.S.

Na+

77 mmol/L

Cl¯

77 mmol/L

pH

4.5 – 7.0

Theor. Osmolarity

154 mOsm/L


Hypotonic Infusion Solution for Intravenous Administration Bottle size: 500 ml * 10 bottles. Sterile, pyrogen free

Kuwait Saudi Pharmaceutical Industries Company

Tel: +965 24745012/3/4

Fax: +965 24745361, P. O. Box: 5512, postal code: 13056 Safat, Kuwait

Website: www.kspico.com


05/2010
  نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)

صوديوم كلوريد ۰,٤٥٪ وزن/ حجم محلول للحقن الوريدي (ب.ف.)

دواعي الاستعمال

§   تعويض السائل البلازمي،

§   التعويض في حالات نقص الكلوريد القلوي أو نقص الصوديوم في الدم،

§   لتعويض السوائل في حالات الجفاف.

نواهي الاستعمال

 

§   حالات ارتفاع الصوديوم في الدم،

§   حالات حموضة الدم،

حالات نقص البوتاسيوم في الدم.

الاحتياطات

لا تستعمله إن وجد تسريب، أو إذا كان المحلول معكر أو يحتوي على شوائب.

https://localhost:44358/Dashboard

عن طريق الحقن الوريدي:

حتى ١٥ مل/ كجم من وزن الجسم/ ساعة أي ۳٥۰ نقطة/ دقيقة/ ٧۰ كجم من وزن الجسم.

 

الجرعة المتوسطة:

١۰۰۰ – ۲۰۰۰ مل/ ٧۰ كجم من وزن الجسم/ يوم.

غير متاح

يحفظ في درجة حرارة أقل من ٢٥ درجة مئوية.

يحتوي كل ١۰۰ مل من المحلول على:

 

صوديوم كلوريد

۰,٤٥ جم

ماء للحقن

بقية المحلول

كاتيونات الصوديوم

٧٧ ملي مول/ لتر

آنيونات الكلوريد

٧٧ ملي مول/ لتر

الأس الهيدروجيني (معدل الحموضة)

٤,٥ – ٧,۰

الضغط الأسموزي الافتراضي

١٥٤ ملي اوزم/ لتر

محلول للحقن الوريدي منخفض الضغط الاسموزي

عبوة حجم: ٥۰۰ مل X ١۰ عبوات

معقم و خالي من الحميات.

الشركة المصنعة والمفوضة بالتسويق

الشركة الكويتية السعودية للصناعات الدوائيه

ص ب: 5512 ،الرمز البريدي: 13056 الصفاة، الكويت

هاتف: 96524745013-96524745014+

فاكس: 96524745361+

الموقع الالكتروني: www.kspico.com

05/2010
 Read this leaflet carefully before you start using this product as it contains important information for you

Sodium Chloride 0.45% w/v Intravenous Infusion B.P.

Each 100 ml contains: Sodium Chloride 0.45 g Water for Injection Q.S. Na+ 77 mmol/L Cl- 77 mmol/L pH 4.5 - 7.0 Theor. Osmolarity 154 mOsm/L (For full list of excipients, see section 6.1)

Sodium Chloride 0.45% w/v Intravenous Infusion B.P. Hypotonic Solution for Intravenous Administration.

Sodium Chloride 0.45% Solution for Infusion is indicated for the treatment of hypertonic extracellular dehydration or hypovolaemia in cases where the intake of fluids and electrolytes by normal routes is not possible.

It can also be used as a vehicle or diluent of compatible medicinal products.


Posology

Adults, older people, adolescents and children:

The dosage, rate and duration of administration is to be individualised as determined by several factors including age, weight, clinical condition, concomitant treatment and in particular the patient's hydration state, clinical and laboratory response to treatment. Fluid balance and plasma electrolyte concentrations must be monitored during treatment.

- Recommended dosage For adults, older people and adolescents: 500 ml to 3 litres/24h,

- For babies and children: 20 to 100 ml per 24 h and per kg of body weight, depending on the age and the total body mass.

The recommended dosage when used as a vehicle or diluent ranges from 50 to 250 ml per dose of medicinal product to be administered.

 

Administration rate:

The infusion rate depends on the patient clinical conditions. It is usually:

§ 40 ml/kg/24h for adults, older people and adolescents,

§ 5 ml/kg/h in average for paediatric patients but the value varies with age:

§ 6-8 ml/kg/h for infants,

§ 4-6 ml/kg/h for toddlers,

§ 2-4 ml/kg/h for schoolchildren.

 

Note:

- Infants and toddlers: age ranges from about 28 days to 23 months (a toddler is an infant who can walk)

 

- Children and schoolchildren: age ranges from about 2 years to 11 years.

When Sodium Chloride 0.45% Solution for Infusion is used as a diluent for injectable preparations of other medicinal products, the infusion rate will also be dictated by the nature and the dose regimen of the prescribed medicinal products.

 

Method of Administration:

The solution is for administration by intravenous infusion through a sterile and non-pyrogenic administration set, using aseptic technique. The equipment should be primed with the solution in order to prevent air entering the system.

The product should be inspected visually for particulate matter and discoloration prior to administration. Do not administer unless solution is clear, free from visible particles and the seal is intact

Administer immediately following the insertion of infusion set.

Do not connect flexible plastic containers in series in order to avoid air embolism due to possible residual air contained in the primary container. Pressurizing intravenous solutions contained in flexible plastic containers to increase flow rates can result in air embolism if the residual air in the container is not fully evacuated prior to administration. Use of a vented intravenous administration set with the vent in the open position could result in air embolism. Vented intravenous administration sets with the vent in the open position should not be used with flexible plastic containers.

Additives may be introduced before infusion or during infusion through the injection site. Adding other medication or using an incorrect administration technique might cause the appearance of fever reactions due to the possible introduction of pyrogens. If an adverse event occurs the patient evaluated and appropriate countermeasures started, if needed the infusion should be stopped.

For information on incompatibilities and preparation of the product with additives, please see sections 6.2 and 6.6.


The solution is contra-indicated in patient presenting:  Hyponatraemia, hypochloraemia,  Extracellular hyperhydration or hypervolaemia,  Severe renal insufficiency (with oliguria/anuria),  Fluid and sodium retention,  Uncompensated cardiac failure,  General oedema and ascitic cirrhosis. The contra-indications related to the added medicinal product should be considered.

Electrolyte balance

Hyponatraemia/Hypernatraemia

The infusion of solutions with sodium concentrations <0.9% may result in hyponatraemia. Close clinical monitoring may be warranted. Hyponatraemia can lead to headache, nausea, seizures, lethargy, coma, cerebral oedema and death.

 

The risk for hyponatraemia is increased, for example,

§ in children

§ in elderly patients

§ in women

§ postoperatively

§ in persons with psychogenic polydipsia

§ in patients treated with medications that increase the risk of hyponatraemia (such as certain antiepileptic and psychotropic medications).

 

The risk for developing hyponatraemic encephalopathy is increased, for example,

§ in paediatric patients (≤16 years of age)

§ in women (in particular pre-menopausal women)

§ in patients with hypoxemia

§ in patients with underlying central nervous system disease

Acute symptomatic hyponatraemic encephalopathy is considered a medical emergency.

Hyponatraemia should be corrected at a calculated rate to prevent hyponatraemic encephalopathy.

Rapid correction of hyponatraemia and hypernatremia is potentially dangerous (risk of serious neurologic complications). Rapidly correcting hypernatremia once adaptation has occurred may lead to cerebral oedema, potentially resulting in seizures, permanent brain damage, or death.

Dosage, rate, and duration of administration should be determined by a physician experienced in intravenous fluid therapy

 

Fluid balance/renal function

Use in patients with moderate renal impairment

The product should be administered with particular caution, to patients with moderate renal impairment. In such patients administration of Sodium Chloride 0.45% Solution for Infusion may result in sodium retention.

 

Risk of fluid and/or solute overload and electrolyte disturbances

Depending on the volume and rate of infusion, intravenous administration of Sodium Chloride 0.45% Solution for Infusion can cause

§ Fluid and/or solute overload resulting in over hydration/hypervolemia and, for example, congested states, including central and peripheral oedema.

§ Clinically relevant electrolyte disturbances and acid-base imbalance.

In general; the risk of dilutional states is inversely proportional to the electrolyte concentrations in the solution and additions. The risk of solute overload causing congested states is directly proportional to the electrolyte concentration in the solution and its additions.

Clinical evaluation and periodic laboratory determinations may be necessary to monitor changes in fluid balance, electrolyte concentrations, and acid-base balance during prolonged parenteral therapy or whenever the condition of the patient or the rate of administration warrants such evaluation.

 

Use in patients at risk for sodium retention, fluid overload and oedema

Sodium Chloride 0.45% Solution for Infusion should be used with particular caution, if at all, in patients with or at risk for:

§ Hypervolemia

§ Conditions that may cause sodium retention, fluid overload and oedema (central and peripheral), such as patients with

o primary hyperaldosteronism,

o secondary hyperaldosteronism associated with, for example,

- hypertension,

- congestive heart failure,

- liver disease (including cirrhosis),

- renal disease (including renal artery stenosis, nephrosclerosis) or

- pre-eclampsia.

Medications that may increase the risk of sodium and fluid retention, such as corticosteroids

 

Infusion reactions

Symptoms of unknown aetiology which can appear to be hypersensitivity reactions have been reported very rarely in association with parenteral infusion of Sodium Chloride. These have been characterized as hypotension, pyrexia, tremor, chills, urticaria, rash and pruritus. Stop the infusion immediately if signs or symptoms of these reactions develop. Appropriate therapeutic countermeasures should be instituted as clinically indicated.

 

Specific patient groups

The consulting physician should be experienced in this product's use and safety in these special populations that are especially sensitive to rapid changes in serum sodium levels.

Rapid correction of hyponatraemia and hypernatremia is potentially dangerous (risk of serious neurologic complications). See section “Hyponatraemia/hypernatraemia” above.

 

Paediatric population

Plasma electrolyte concentrations should be closely monitored in the paediatric population as this population may have impaired ability to regulate fluids and electrolytes. Repeated infusions of sodium chloride should only be given after determination of serum sodium level.

The infusion of hypotonic fluids together with the non-osmotic secretion of ADH may result in hyponatraemia. Hyponatraemia can lead to headache, nausea, seizures, lethargy, coma, cerebral oedema and death, therefore acute symptomatic hyponatraemic encephalopathy is considered a medical emergency.

 

Geriatric population

In older people, the risk for hyponatraemia is increased. When selecting the type of infusion solution and the volume/rate of infusion for a geriatric patient, consider that geriatric patients are generally more likely to have cardiac, renal, hepatic, and other diseases or concomitant drug therapy.

 

Other warnings

Osmolarity

Sodium Chloride 0.45% Solution for Infusion is hypotonic with an osmolarity of approximately 154 mOsmol/L.

 

Administration with Blood Products

Do not mix or administer Sodium Chloride 0.45% Solution for Infusion through the same administration set with whole blood or cellular blood components.

During long-term infusion, the doctor can decide to give you an appropriate nutritive supply.

As with all parenteral solutions, compatibilities should be checked when additives are used (see section 6.2).


Interaction related to the presence of sodium:

Corticoids/Steroids and carbenoxolone, which are associated with the retention of sodium and water (with oedema and hypertension), see section 4.4 special warnings and precautions for use.

Drugs leading to an increased vasopressin effect:

The below listed drugs increase the vasopressin effect, leading to reduced renal electrolyte free water excretion and may increase the risk of hospital acquired hyponatraemia following inappropriately balanced treatment with i.v. fluids (see sections 4.2, 4.4 and 4.8).

• Drugs stimulating vasopressin release include: Chlorpropamide, clofibrate, carbamazepine, vincristine, selective serotonin reuptake inhibitors, 3.4-methylenedioxy-N-methamphetamine, ifosfamide, antipsychotics, narcotics

• Drugs potentiating vasopressin action include: Chlorpropamide, NSAIDs, cyclophosphamide

• Vasopressin analogues include: Desmopressin, oxytocin, terlipressin

Other medicinal products increasing the risk of hyponatraemia also include diuretics in general and antiepileptics such as oxcarbazepine.

Caution is advised in patients treated with lithium. Renal sodium and lithium clearance may be decreased in the presence of hyponatraemia. Administration of Sodium Chloride 0.45% Solution for Infusion may result in increased lithium levels.


There are no adequate data from the use Sodium Chloride 0.45% Solution for Infusion in pregnant or lactating women. The physician should carefully consider the potential risks and benefits for each specific patient before administering Sodium Chloride 0.45% Solution.

Sodium Chloride 0.45% Solution for Infusion should be administrated with special caution for pregnant women during labour particularly as to serum-sodium if administered in combination with oxytocin (see section 4.4, 4.5 and 4.8).

When a medicinal product is added, the nature of the drug and its use during pregnancy and lactation have to be considered separately.


There is no information on the effects of Sodium Chloride 0.45% Solution for Infusion on the ability to operate an automobile or other heavy machinery


The following undesirable effects have been reported to have occurred during or following infusion of Sodium Chloride 0.45% Solution for Infusion. The frequency of the adverse drug reactions listed in this section cannot be estimated from the available data

 

 

 

 

 

 

System Organ Class

Symptoms (LLT terms MedDRA)

Metabolism and nutrition disorders

Overhydration* (associated or not with polyuria) in patients with cardiac disorder or pulmonary oedema

Asymptomatic electrolyte disturbance

Hyponatraemia

Hospital acquired hyponatraemia**

Nervous system disorders


Acute hyponatraemic encephalopathy**

 

Cardiac disorders

Heart failure in patients with cardiac disorder or pulmonary oedema

Vascular disorders

Thrombophlebitis*

Venous thrombosis*

General disorders and administration site conditions

Fever*

Injection site pain*

Injection site reaction*

Injection site phlebitis*

Injection site irritation*

Injection site infection*

Extravasation*

 

The frequency of the adverse drug reactions listed in this section cannot be estimated from the available data

* Adverse reactions associated with the technique of administration

**Hospital acquired hyponatraemia may cause irreversible brain injury and death, due to development of acute hyponatraemic encephalopathy, frequency unknown (see sections 4.2. 4.4, 4.5).

 

The following adverse reactions have not been reported with this product but may occur:

§ Hyperchloraemic metabolic acidosis

§ Infusion reactions, including hypotension, tremor, chills, urticaria, rash, and pruritus.

Adverse reactions may be associated to the medicinal products added to the solution; the nature of the additive will determine the likelihood of any other undesirable effects.

If an adverse event occurs the patient should be evaluated and appropriate countermeasures started, if needed the infusion should be stopped

 

Adverse Drug Reaction (ADR) Reporting

·   Saudi Arabia:

 

The National Pharmacovigilance and Drug Safety Centre (NPC)

§ Fax: +966-11-205-7662

§ Call NPC at: +966-11-2038222, Ext.: 2317-2356-2353-2354-2334-2340.

§ Toll free phone: 8002490000

§ E-mail:npc.drug@sfda.gov.sa

§ Website: www.sfda.gov.sa/npc


An excessive volume of Sodium Chloride 0.45% Solution for Infusion may lead to:

§ hypo- and hypernatremia (which can lead to CNS manifestations, including seizures, coma, cerebral oedema and death) and

§ sodium overload (which can lead to central and/or peripheral oedema).

See also section 4.4.

Excessive administration of chloride salts may cause a loss of bicarbonate with an acidifying effect.

When Sodium Chloride 0.45% Solution for Infusion is used as a diluent for injectable preparations of other medicinal products, the signs and symptoms of over infusion will be related to the nature of the additives being used.

In the event of accidental over infusion, treatment should be discontinued and the patient should be observed for the appropriate signs and symptoms related to the drug administered. The relevant and supportive measures should be provided as necessary.

 


Pharmacotherapeutic group: “Electrolyte solutions”,

ATC code: B05XA03.

Sodium Chloride 0.45% Solution for Infusion is a hypotonic solution, with an approximate osmolarity of 154 mOsm/l.

The pharmacodynamic properties of the solution are those of the sodium and chloride ions in maintaining the fluid and electrolyte balance. Ions, such as sodium, circulate through the cell membrane, using various mechanisms of transport, among which is the sodium pump (Na-K-ATPase). Sodium plays an important role in neurotransmission and cardiac electrophysiology, and also in renal function.

Chloride is mainly an extracellular anion. Intracellular chloride is in high concentration in red blood cells and gastric mucosa. Reabsorption of chloride follows reabsorption of sodium.

When medication is added to Sodium Chloride 0.45% Solution for Infusion, the overall pharmacodynamics of the solution will depend on the nature of the medicinal product used.


Sodium and Chloride are mainly distributed in blood and extracellular compartiments (Na+: 142 mmol/l – Cl-: 103 mmol/l).

Sodium is predominantly excreted by the kidney with a renal reabsorption.

Small amounts of sodium are lost in the faeces and sweat at the skin level.

When medication is added to Sodium Chloride 0.45% Solution for Infusion, the overall pharmacokinetics of the solution will depend on the nature of the medicinal product used.


Preclinical safety data of this solution for infusion in animals are not relevant since its constituents are physiological components of animal and human plasma.

Toxic effects are not to be expected under the condition of clinical application.

The safety of potential additives should be considered separately.

 


The excipient in each 100 ml is:

Water for Injection………………………….Q.S. to 100 ml


Incompatibility of the medicinal product to be added to the solution in container must be assessed before addition. Those additives known to be incompatible should not be used.

In the absence of compatibility studies, this solution must not be mixed with other medicinal products See section 6.6 for further instructions on the use of the product with additives


5 years from the manufacturing date. The expiry date refers to the last day of the month. From a microbiological point of view, the diluted product must be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C unless reconstitution has taken place in controlled and validated aseptic conditions.

§ Keep in a safe place, out of the reach and sight of children.

§ Store below 25º C.

 


Bottle size: 500 ml × 10 bottles

Sterile and pyrogen free


Please see section 4.2 for information regarding the method of administration.

Before adding a drug, verify it is soluble and stable in water at the pH range of the Sodium Chloride 0.45% Solution for Infusion (pH 4.5 to 7.0). Additives may be introduced before infusion or during infusion through the injection site.

It is the responsibility of the healthcare professional to judge the incompatibility of an additive medication with the Sodium Chloride 0.45% Solution for Infusion, by checking for eventual colour change and/or eventual appearance of precipitate, insoluble complexes or crystals. The instruction for use of the medicinal product to be added must be consulted.

When additive is used, verify isotonicity prior to parenteral administration. Thorough and careful aseptic mixing of any additive is mandatory. Solutions containing additives should be used immediately and not stored.

Discard after single use.

Discard any unused portion.

Do not reconnect partially used bottle.

1. Opening

If leaks are found, discard solution, as sterility may be broken.

Check the solution for clarity and absence of foreign matters. If solution is not clear or contains foreign matters, discard the solution.

2. Preparation for administration

Use sterile material for preparation and administration.

a. Suspend container from eyelet support.

b. Remove plastic protector from outlet port at bottom of container:

c. Use an aseptic method to set up the infusion.

d. Attach administration set. Refer to complete directions accompanying set for connection, priming of the set and administration of the solution.

3. Techniques for injection of additive medications

Warning: Additives may be incompatible.

To add medication before administration

a. Disinfect medication site.

b. Using syringe with 19 (1.10 mm) to 22 (0.70 mm) gauge needle, puncture resealable medication port and inject.

c. Mix solution and medication thoroughly. For high-density medication such as potassium chloride, tap the ports gently while ports are upright and mix.

Caution: Do not store bottle containing added medications.

To add medication during administration

a. Close clamp on the set.

b. Disinfect medication site.

c. Using syringe with 19 (1.10 mm) to 22 (0.70 mm) gauge needle, puncture resealable medication port and inject.

d. Remove container from IV pole and/or turn to an upright position.

e. Evacuate both ports by tapping gently while the container is in an upright position.

f. Mix solution and medication thoroughly.

g. Return container to in use position, re-open the clamp and continue administration.


Kuwait Saudi Pharmaceutical Industries Company Tel: +965 24745012/3/4 Fax: +965 24745361, P. O. Box: 5512, postal code: 13056 Safat, Kuwait Website: www.kspico.com

27/04/2020
}

صورة المنتج على الرف

الصورة الاساسية